Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

Technology to assess vascular health


總結

Visualize: Vascular- Technology to assess vascular health. Visualize: Vascular effectively tracks the active intraluminal arterial pathway rendering the lumen in 3D. It allows the clinician to focus on the residual lumen by essentially removing the other image content to reveal a 3D rendering of the active conduit through which the blood flows. Visualize is a distinctive and separately defined exam. It does not use the velocity or color data typically captured during a vascular ultrasound exam. There is a specific protocol for acquiring images which collects about 300 frames for 3D rendering. B-CAD computer-aided detection finds the edge of the lesion, characterizes the lesion acquired using breast ultrasound imaging to help physicians better understand whether solid nodules may be benign or malignant. The ACR BI-RADS® lexicon defines a method for lesion characterization that has been shown to increase diagnostic accuracy. B-CAD utilizes more than 14,000 pathology-proven patient inputs that were read and marked by a panel of breast lesion experts using the BI- RADS system, to develop the algorithm for comprehensive diagnostic support for breast lesion analysis.
Visualize: Vascular -评估血管健康的技术。Visualize: Vascular可有效追踪活跃管腔内的动脉通路, 3D渲染血管内腔。它通过基本去除其他图像内容,显现3D渲染的血液流动的活跃血管,来使临床医生集中在剩下的内腔上。Visualize是个与众不同且单独设立的检查。它不使用通常血管超声检查获得的流速或颜色数据,而是有可以搜集约300帧3D渲染来获得图像的特殊方法。 B-CAD 计算机-辅助检测发现病灶边缘,通过分析胸部超声成像获得的病变帮助医生更好的了解实行结节是良性还是恶性的。 ACR BI‐RADS®明确了一个病变鉴定的新方法,已证明可提高诊断的准确性。B-CAD 利用胸部病变专家小组标记确诊的超过14,000例病例,通过BI- RADS 系统输入后开发用于胸部病灶分析的全面诊断支持算法。Clinical Applications: Vascular and Breast Imaging
临床应用: 血管和胸部影像


詳細技術說明

Stage: Technologies are approved in US and Canada. They are seeking buyers for IP or joint venture and financing opportunities.
阶段: 通过美国和加拿大专利申请,正在寻找许可或成立合资企业的合作方,或融资机会


合作類型

技术售让


覆蓋範圍

生物技术/制药/医疗


商品和服務

药械组合

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版